Quick Takeaways
- Shay Capital LLC filed SCHEDULE 13G for LAVA Therapeutics NV Common shares, par value (euro) 0.12 per share (LVTX).
- Disclosed ownership: 9.9%.
- Date of event: 19 Sep 2025.
Shay Capital LLC - 19 Sep 2025 SCHEDULE 13G Report for LAVA Therapeutics NV Common shares, par value (euro) 0.12 per share (LVTX)
- Filing Manager
- Shay Capital LLC
- Reporting Manager
- Shay Capital LLC
- Symbol
- LVTX
- Shares outstanding
- 26,226,293 shares
- Disclosed Ownership
- 2,596,403 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 26 Sep 2025, 16:01:22 UTC
- Date of event
- 19 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Shay Capital LLC disclosed 9.9% ownership in LAVA Therapeutics NV Common shares, par value (euro) 0.12 per share (LVTX) on 19 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 26 Sep 2025, 16:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Shay Capital LLC | 9.9% | 2,596,403 | 2,596,403 | 0 | Elan Foxman | Chief Financial Officer | |
| Shay Capital Holdings LLC | 9.9% | 2,596,403 | 2,596,403 | 0 | Elan Foxman | Chief Financial Officer |